Expanding the Role for Immunotherapy in Triple-Negative Breast Cancer

被引：37

作者：

Savas, Peter ^{[1
]}

Loi, Sherene ^{[1
,2
]}

机构：

[1] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[2] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia

来源：

CANCER CELL | 2020年 / 37卷 / 05期

关键词：

D O I：

10.1016/j.ccell.2020.04.007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PD-1 axis blockade, in combination with chemotherapy, improves outcomes in advanced triple-negative breast cancer that is PD-L1 positive. The phase 3 KEYNOTE-522 trial now shows that the addition of pembro-lizumab to chemotherapy improves pathological complete response rates regardless of PD-L1 status and appears to improve survival.

引用

页码：623 / 624

页数：2

共 9 条

[1]

Adams S., 2019, Ann. Oncol

[2] Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J].

Cortazar, Patricia ;

Zhang, Lijun ;

Untch, Michael ;

Mehta, Keyur ;

Costantino, Joseph P. ;

Wolmark, Norman ;

Bonnefoi, Herve ;

Cameron, David ;

Gianni, Luca ;

Valagussa, Pinuccia ;

Swain, Sandra M. ;

Prowell, Tatiana ;

Loibl, Sibylle ;

Wickerham, D. Lawrence ;

Bogaerts, Jan ;

Baselga, Jose ;

Perou, Charles ;

Blumenthal, Gideon ;

Blohmer, Jens ;

Mamounas, Eleftherios P. ;

Bergh, Jonas ;

Semiglazov, Vladimir ;

Justice, Robert ;

Eidtmann, Holger ;

Paik, Soonmyung ;

Piccart, Martine ;

Sridhara, Rajeshwari ;

Fasching, Peter A. ;

Slaets, Leen ;

Tang, Shenghui ;

Gerber, Bernd ;

Geyer, Charles E., Jr. ;

Pazdur, Richard ;

Ditsch, Nina ;

Rastogi, Priya ;

Eiermann, Wolfgang ;

von Minckwitz, Gunter .

LANCET, 2014, 384 (9938) :164-172

[3] Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype Shifts [J].

Hutchinson, Katherine E. ;

Yost, Susan E. ;

Chang, Ching-Wei ;

Johnson, Radia Marie ;

Carr, Adrian R. ;

McAdam, Paul R. ;

Halligan, Daniel L. ;

Chang, Chun-Chieh ;

Schmolze, Daniel ;

Liang, Jackson ;

Yuan, Yuan .

CLINICAL CANCER RESEARCH, 2020, 26 (03) :657-668

[4] Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy [J].

Im, Se Jin ;

Hashimoto, Masao ;

Gerner, Michael Y. ;

Lee, Junghwa ;

Kissick, Haydn T. ;

Urger, Matheus C. B. ;

Shan, Qiang ;

Hale, J. Scott ;

Lee, Judong ;

Nasti, Tahseen H. ;

Sharpe, Arlene H. ;

Freeman, Gordon J. ;

Germain, Ronald N. ;

Nakaya, Helder I. ;

Xue, Hai-Hui ;

Ahmed, Rafi .

NATURE, 2016, 537 (7620) :417-+

[5] Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers [J].

Loi, Sherene ;

Drubay, Damien ;

Adams, Sylvia ;

Pruneri, Giancarlo ;

Francis, Prudence A. ;

Lacroix-Triki, Magali ;

Joensuu, Heikki ;

Dieci, Maria Vittoria ;

Badve, Sunil ;

Demaria, Sandra ;

Gray, Robert ;

Munzone, Elisabetta ;

Lemonnier, Jerome ;

Sotiriou, Christos ;

Piccart, Martine J. ;

Kellokumpu-Lehtinen, Pirkko-Liisa ;

Vingiani, Andrea ;

Gray, Kathryn ;

Andre, Fabrice ;

Denkert, Carsten ;

Salgado, Roberto ;

Michiels, Stefan .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07) :559-+

[6] A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study [J].

Loibl, S. ;

Untch, M. ;

Burchardi, N. ;

Huober, J. ;

Sinn, B., V ;

Blohmer, J-U ;

Grischke, E-M ;

Furlanetto, J. ;

Tesch, H. ;

Hanusch, C. ;

Engels, K. ;

Rezai, M. ;

Jackisch, C. ;

Schmitt, W. D. ;

von Minckwitz, G. ;

Thomalla, J. ;

Kuemmel, S. ;

Rautenberg, B. ;

Fasching, P. A. ;

Weber, K. ;

Rhiem, K. ;

Denkert, C. ;

Schneeweiss, A. .

ANNALS OF ONCOLOGY, 2019, 30 (08) :1279-1288

[7] Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial [J].

Nanda, Rita ;

Liu, Minetta C. ;

Yau, Christina ;

Shatsky, Rebecca ;

Pusztai, Lajos ;

Wallace, Anne ;

Chien, A. Jo ;

Forero-Torres, Andres ;

Ellis, Erin ;

Han, Heather ;

Clark, Amy ;

Albain, Kathy ;

Boughey, Judy C. ;

Jaskowiak, Nora T. ;

Elias, Anthony ;

Isaacs, Claudine ;

Kemmer, Kathleen ;

Helsten, Teresa ;

Majure, Melanie ;

Stringer-Reasor, Erica ;

Parker, Catherine ;

Lee, Marie C. ;

Haddad, Tufia ;

Cohen, Ronald N. ;

Asare, Smita ;

Wilson, Amy ;

Hirst, Gillian L. ;

Singhrao, Ruby ;

Steeg, Katherine ;

Asare, Adam ;

Matthews, Jeffrey B. ;

Berry, Scott ;

Sanil, Ashish ;

Schwab, Richard ;

Symmans, W. Fraser ;

van't Veer, Laura ;

Yee, Douglas ;

DeMichele, Angela ;

Hylton, Nola M. ;

Melisko, Michelle ;

Perlmutter, Jane ;

Rugo, Hope S. ;

Berry, Donald A. ;

Esserman, Laura J. .

JAMA ONCOLOGY, 2020, 6 (05) :676-684

[8]

Schmid P, 2020, NEW ENGL J MED, V382, P810, DOI [10.1056/NEJMoa1910549, 10.1056/NEJMc2006684]

[9] Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial [J].

Schmid, Peter ;

Rugo, Hope S. ;

Adams, Sylvia ;

Schneeweiss, Andreas ;

Barrios, Carlos H. ;

Iwata, Hiroji ;

Dieras, Veronique ;

Henschel, Volkmar ;

Molinero, Luciana ;

Chui, Stephen Y. ;

Maiya, Vidya ;

Husain, Amreen ;

Winer, Eric P. ;

Loi, Sherene ;

Emens, Leisha A. .

LANCET ONCOLOGY, 2020, 21 (01) :44-59

← 1 →